Restricted accessResearch articleFirst published online 2022-9
The utility of erythrocyte sedimentation rate,C-reactive protein,and procalcitonin in detecting infections in patients with systemic lupus erythematosus: A systematic review
We conducted a systematic review with metanalysis to investigate the utility of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and procalcitonin (PCT) in diagnosing infections in hospitalized patients with SLE.
Methods
We searched Medline, Embase, Web of Science, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials (CENTRAL) with a search strategy developed by a medical librarian. We included retrospective, cross-sectional, case-control, and prospective studies in our analysis. We used the Quality Assessment of Diagnostic Studies (QUADAS-2) to assess for bias and applicability. We obtained mean differences, sensitivities, and specificities in our analysis.
Results
We included 26 studies in our analysis. Most studies had an unclear or high risk of bias and our results were widely heterogenous. For the diagnosis of infections, the CRP had a pooled sensitivity of 0.75 (95%CI 0.57-0.94) and specificity of 0.72 (0.59-0.85), PCT had a pooled sensitivity of 0.68 (95% CI 0.0.59–0.77) and specificity of 0.75 (0.59–0.90), and for ESR pooled estimates were not calculated but sensitivity ranged from 50 to 69.8 and specificity from 38.5 to 55.6. Modifying cut-offs improved sensitivities and specificities. The ESR, CRP, and PCT mean differences were all greater in infection groups versus non-infection (10.1, 95% CI 3.2–17.0; 46.8, 95% CI 36.5–57.0; 0.53, 95% CI 0.26–0.80; respectively).
Discussion
Poor sensitivities and specificities were observed for the evaluated biomarkers with substantial heterogeneity in the cut-offs used to determine infection. Although mean biomarker values were increased in the infection group compared with the non-infection, our findings do not support the widespread use of ESR, CRP, or PCT in diagnosing infection in hospitalized patients with SLE due to increased heterogeneity and risk of bias. Further investigation is needed.
LeeJPeschkenCMuangchanC, et al.The frequency of and associations with hospitalization secondary to lupus flares from the 1000 faces of lupus Canadian cohort. Lupus2013; 22(13): 1341–1348.
2.
LiangHPanH-FTaoJ-HYeD-Q. Causes and factors associated with frequent hospitalization in chinese patients with systemic lupus erythematosus: an ambispective cohort study. Med Sci Monit2019; 25: 8061–8068.
3.
MinneciPCDeansKJEichackerPQNatansonC. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infec2009; 15(4): 308–318.
4.
StolzDChrist-CrainMBingisserR, et al.Antibiotic treatment of exacerbations of COPD. Chest2007; 131: 9–19.
ZhaiXFengMGuoH, et al.Development of prediction models for new integrated models and a bioscore system to identify bacterial infections in systemic lupus erythematosus. Front Cell Infect Microbiol2021; 11: 620372.
7.
AlJarhiUMSadekKMDarwishEM, et al.Evaluation of serum presepsin, procalcitonin, copeptin, and high-sensitivity C-reactive protein for differentiating bacterial infection from disease activity in Egyptian patients with systemic lupus erythematosus. Clin Rheumatol2021; 40: 1861–1869.
8.
AlurSMary ThabahMSistlaSSingh NegiV. Occurrence, predictors and outcome of infections at three months in hospitalized patients with SLE: a prospective study from Southern India. Lupus2020; 29: 649–658.
9.
ZabidiNFAThevarajahTM. Serum procalcitonin measurement for the detection of bacterial infection vs disease flare and viral infection in sle patients. Clinica Chimica Acta2019; 493: S104.
10.
Deeks JJ, Bossuyt PM, Leeflang M, Yakwoingi Y and Flemyng E (eds). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2021. Available from srdta.cochrane.org.
11.
McInnesMDFMoherDThombsBD, et al.Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies. JAMA2018; 319: 388–396.
12.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
13.
PetriMOrbaiAMAlarcónGS, et al.Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
14.
AringerMCostenbaderKDaikhD, et al.2019 European league against rheumatism/american college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol2019; 71: 1400–1412.
15.
FengMZhangSLLiangZJ, et al.Peripheral neutrophil CD64 index combined with complement, CRP, WBC count and B cells improves the ability of diagnosing bacterial infection in SLE. Lupus2019; 28: 304–316.
16.
ReutersT. EndNote X9. Computer program, 2019.
17.
Review Manager (RevMan). [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.
18.
WhitingPFRutjesAWSWestwoodME, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med2011; 155: 529–536.
19.
BadorKIntanSHussinSGaforA. Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus2012; 21: 1172–1177.
20.
GuyattGHOxmanADVistGE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008; 336: 924–926.
21.
AjmaniSSinghHChaturvediS, et al.Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCA-associated vasculitis. Clin Rheumatol2019; 38: 997–1005.
22.
BeçaSRodríguez-PintóIAlbaMACerveraREspinosaG. Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. Autoimmun Rev2015; 14: 586–593.
23.
BeckerGJWaldburgerMHughesGRPepysMB. Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum dis1980; 39: 50–52.
24.
Broca-GarciaBESaavedraMAMartínez-BencomoMA, et al.Utility of neutrophil-to-lymphocyte ratio plus C-reactive protein for infection in systemic lupus erythematosus. Lupus2019; 28: 217–222.
25.
ChenCHTaiSBChenHCYangDHPengMYLinYF. Analysis of erythrocyte C4d to complement receptor 1 ratio: use in distinguishing between infection and flare-up in febrile patients with systemic lupus erythematosus. BioMed Res Int2015; 2015: 939783.
26.
EcheverriANaranjo-EscobarJPosso-OsorioI, et al.Neutrophil CD64 expression, procalcitonin and presepsin are useful to differentiate infections from flares in SLE patients with SIRS. Lupus2018; 27: 1130–1139.
27.
FakhreldinSGamalSMSaadAS. Predictive potential of the disease activity index and C-reactive protein for infection in systemic lupus erythematosus patients. Egypt Rheumatol2015; 37: 171–175.
28.
FiroozNAlbertDWallaceDIshimoriMBerelDWeismanM. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus2011; 20: 588–597.
29.
HoCHLeungAMH. Role of procalcitonin and c-reactive protein in screening of infection in patients with systemic lupus erythematosus. Poster Present2017; 588: 2–9.
30.
InoueTTakedaTKodaS, et al.Differential diagnosis of fever in systemic lupus erythematosus using discriminant analysis. Rheumatol Int1986; 6: 69–77.
31.
KimH-AJungJ-YSuhC-H. Usefulness of neutrophil-to-lymphocyte ratio as a biomarker for diagnosing infections in patients with systemic lupus erythematosus. Clin Rheumatol2017; 36: 2479–2485.
32.
LinWChenP. Tubercular meningitis in patients with systemic lupus erythematosus: clinical characteristics, risk factors, and outcomes of 10 patients. Clin Rheumatol2020; 39: 1141–1145.
33.
LittlejohnEMarderWLewisE, et al.The ratio of erythrocyte sedimentation rate to c-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever. Lupus2018; 27: 1123–1129.
34.
LuZLiJJiJGuZDaZ. Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections. Braz J Med Biol Res2019; 52: e8131.
35.
MackiewiczAMarcinkowska-PietaRBallouSMackiewiczSKushnerI. Microheterogeneity of alpha1-acid glycoprotein in the detection of intercurrent infection in systemic lupus erythematosus. Arthritis Rheum1987; 30: 513–518.
36.
PatrickJMarpaungBGintingY. Differences of serum procalcitonin levels between bacterial infection and flare in systemic lupus erythematosus patients. IOP Conf Ser: Earth Environ Sci2018; 125: 012157.
37.
PyoJParkJParkY-BLeeS-KHaY-JLeeS-W. Delta neutrophil index as a marker for differential diagnosis between flare and infection in febrile systemic lupus erythematosus patients. Lupus2013; 22: 1102–1109.
38.
SchäferVSWeissKKrauseASchmidtWA. Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity. Clin Rheumatol2018; 37: 1835–1844.
39.
ShinKCKangSWBaekHJKimHASongYW. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis2001; 60: 988–989.
40.
WangK-CLiuP-HYuK-H, et al.Is initial C-reactive protein level associated with corticosteroid use in lupus erythematosus patients during a bacterial infection episode?Immunol Lett2017; 185: 84–89.
41.
WangJNiuRJiangL, et al.The diagnostic values of C-reactive protein and procalcitonin in identifying systemic lupus erythematosus infection and disease activity. Medicine2019; 98: e16798.
42.
YuJXuBHuangY, et al.Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Modern Rheumatol2014; 24: 457–463.
43.
JooKParkWLimM-JKwonS-RYoonJ. Serum procalcitonin for differentiating bacterial infection from disease flares in patients with autoimmune diseases. J Korean Med Sci2011; 26: 1147–1151.
44.
HerrmannKSchinkeSCsernokEMoosigFHolleJU. Diagnostic value of procalcitonin in ANCA-associated vasculitis (AAV) to differentiate between disease activity, infection and drug hypersensitivity. Open Rheumatol J2015; 9: 71–76.
45.
WuJ-YLeeS-HShenC-J, et al.Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum2012; 64: 3034–3042.
46.
GaitondeSSamolsDKushnerI. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum2008; 59: 1814–1820.
47.
LiuL-NWangPGuanS-Y, et al.Comparison of plasma/serum levels of procalcitonin between infection and febrile disease flare in patients with systemic lupus erythematosus: a meta-analysis. Rheumatol Int2017; 37: 1991–1998.
48.
ChenYShenJYangHXuSMaYPanF. Serum procalcitonin and C-reactive protein levels as diagnostic markers for distinguishing bacterial infections from lupus flares in systemic lupus erythematosus: a systematic review and meta analysis. Int Immunopharmacol2021; 101: 108304.
49.
LanoixJBourgeoisASchmidtJ, et al.Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus2011; 20: 125–130.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
